JAMA dermatology最新文献

{"title":"Population Skin Cancer Screening and Melanoma Mortality Rates.","authors":"Joachim Hübner, Laura Schumann, Nora Eisemann, Alexander Katalinic, Julia Beckhaus","doi":"10.1001/jamadermatol.2026.1527","DOIUrl":"10.1001/jamadermatol.2026.1527","url":null,"abstract":"<p><strong>Importance: </strong>In Germany, a population-based skin cancer screening (SCS) program was implemented in 2008. The benefit of the intervention is unclear.</p><p><strong>Objective: </strong>To determine whether the German SCS program was associated with reduced melanoma mortality.</p><p><strong>Design, setting, and participants: </strong>This population-based, ecological comparative effectiveness study compared trends in melanoma mortality from 2009 to 2022 in Germany with those in neighboring countries without population-based SCS using data on melanoma mortality from the official cause-of-death statistics. The total populations of 15 federal states of Germany and 9 neighboring countries were examined. The German federal state of Schleswig-Holstein was excluded from the analysis due to a potential lasting effect of a preceding pilot project, conducted in 2003 and 2004. Data were analyzed from November 7, 2025, to February 11, 2026.</p><p><strong>Exposure: </strong>The German SCS program entitles men and women aged 35 years and older to a visual skin examination every 2 years, regardless of their individual skin cancer risk. The 2-year participation rate was estimated at approximately 32%.</p><p><strong>Main outcomes and measures: </strong>Pooled estimates of annual percentage changes (APCs) in age-standardized melanoma mortality rates in German and non-German control regions were calculated using a random-effects model.</p><p><strong>Results: </strong>Data include a mean of 79.1 million inhabitants in Germany and 164.8 million inhabitants in 9 neighboring countries. Between 2009 and 2022, age-standardized melanoma mortality rates decreased in each included region. In Germany, APCs ranged from -3.8% (95% CI, -5.5% to -2.2%) to -0.1% (95% CI, -1.7% to 1.5%). In the control regions, mortality rates decreased between -3.8% (95% CI, -4.9% to -2.7%) and -1.0% (95% CI, -1.9% to -0.2%) per year. Pooled APC estimates are -1.8% (95% CI, -2.3% to -1.4%) for Germany and -2.2% (95% CI, -2.8% to -1.6%) for the non-German control regions; the difference was not statistically significant (P = .42).</p><p><strong>Conclusions and relevance: </strong>The findings of this ecological study are in line with previous studies that failed to show a melanoma mortality benefit associated with the German SCS program. To enable a well-founded decision on the future of the program, the causes of its poor performance should be investigated.</p>","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":"775-779"},"PeriodicalIF":10.9,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13254806/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148217874","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nocturnal Pruritus Associated With Poultry Red Mite Bites.","authors":"Ran An, Hui Gu, Rui Liu","doi":"10.1001/jamadermatol.2026.1387","DOIUrl":"10.1001/jamadermatol.2026.1387","url":null,"abstract":"","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":"837-838"},"PeriodicalIF":10.9,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148264324","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Absent Original in Smartphone Photography.","authors":"Harrison A Edwards, Philip L Tong","doi":"10.1001/jamadermatol.2026.1828","DOIUrl":"10.1001/jamadermatol.2026.1828","url":null,"abstract":"","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":"861-862"},"PeriodicalIF":10.9,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148308059","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"BRAF Inhibition in Congenital Nevi and Neural Melanosis.","authors":"Brent J Doolan, Rebecca Levy, Tara McKeown, Anirban Das, Vijay Ramaswamy","doi":"10.1001/jamadermatol.2026.1629","DOIUrl":"10.1001/jamadermatol.2026.1629","url":null,"abstract":"","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":"859-861"},"PeriodicalIF":10.9,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148361000","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinicopathologic Features and Long-Term Outcomes of Adult Hypopigmented Mycosis Fungoides.","authors":"Jong Bin Park, Shamir Geller, Viviane Liao, Seda Purnak, Auris Huen, Swaminathan P Iyer, Olivia Pierog, Zachary Leibovit-Reiben, Aaron R Mangold, Jane Scribner, Sai M Talluru, Alyssa L Stockard, Jenna Vroman, Jeffrey Weiner, Pamela B Allen, Sima Rozati","doi":"10.1001/jamadermatol.2026.1793","DOIUrl":"10.1001/jamadermatol.2026.1793","url":null,"abstract":"<p><strong>Importance: </strong>Hypopigmented mycosis fungoides (HMF) is uncommon in adults, and data on clinicopathologic features and long-term outcomes remain sparse.</p><p><strong>Objective: </strong>To investigate the clinicopathologic features and outcomes of adults with HMF in a large multicenter cohort.</p><p><strong>Design, setting, and participants: </strong>This retrospective multicenter cohort study conducted from January 2011 to October 2023 at 6 US tertiary referral centers and included adults (18 years or older at diagnosis) with biopsy-confirmed HMF and hypopigmentation documented at diagnosis, with a median (range) follow-up of 39 (1-347) months. Data were analyzed from February to December 2025.</p><p><strong>Exposures: </strong>Clinical variant, immunophenotype predominance, and polymerase chain reaction-based T-cell receptor (TCR) gene rearrangement in peripheral blood and/or skin.</p><p><strong>Main outcomes and measures: </strong>Best overall response, defined as complete response, partial response, stable disease, or progressive disease, and progression to a higher stage.</p><p><strong>Results: </strong>The cohort included 224 adults with HMF (median [range] age, 44 [18-74] years), of whom 164 (73%) were women (60 men [27%]), 5 (2%) were Asian individuals, 1 (0.4%) was a Hispanic/Latino individual, 1 (0.4%) was a Middle Eastern individual, 19 (8%) were White individuals, and 186 (83%) were Black individuals; 219 (98%) presented with early-stage disease. Most had hypopigmented lesions only (159 [71%]), whereas 65 (29%) exhibited mixed-variant mycosis fungoides; outcomes were similar between groups. Among 141 patients with available immunophenotyping, 88 (63%) had CD8-positive predominance. Among 207 treated patients, most (179 [90%]) received skin-directed therapy alone. Among 198 evaluable patients, the best overall response was complete response for 52 (26%), partial response for 101 (51%), stable disease for 34 (17%), and progressive disease for 11 (6%). Over a median (range) follow-up of 39 (1-347) months, 14 of 224 patients (6%) experienced progression to a higher stage, including 5 of 219 patients (2%) with early-stage disease at baseline who experienced progression to advanced-stage disease. Peripheral blood TCR monoclonality was detected in 23 of 85 tested patients (27%) and was associated with poorer treatment response but not with disease progression.</p><p><strong>Conclusions and relevance: </strong>The finding of this cohort study suggest that adult HMF demonstrated a generally indolent course, with favorable response to skin-directed therapy, irrespective of immunophenotype or mixed-variant presentation. Peripheral blood TCR monoclonality was associated with lower treatment response but not disease progression.</p>","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":"780-786"},"PeriodicalIF":10.9,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13276674/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148264362","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Systemic Proteomic Alterations and Predictive Biomarkers of Paroxetine Response in Refractory Rosacea: A Secondary Analysis of a Randomized Clinical Trial.","authors":"Ben Wang, Xinyi Deng, Yifan Zhang, Xin Xiao, Dan Jian, Wei Shi, Fangfen Liu, Zhixiang Zhao, Yan Tang, Mengting Chen, Zhili Deng, Ji Li, Yingxue Huang, Jundong Huang, Yiya Zhang","doi":"10.1001/jamadermatol.2026.1437","DOIUrl":"10.1001/jamadermatol.2026.1437","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Importance: &lt;/strong&gt;Rosacea is a chronic inflammatory cutaneous disorder characterized by persistent erythema and vascular dysregulation. While paroxetine has shown clinical efficacy in reducing these symptoms, the systemic molecular mechanisms underlying its therapeutic response remain poorly characterized.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Objective: &lt;/strong&gt;To investigate systemic proteomic alterations and identify potential predictive biomarkers in patients with refractory erythematous rosacea following paroxetine treatment.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Design, setting, and participants: &lt;/strong&gt;This prospective plasma proteomic analysis was nested within a multicenter, randomized, double-blind, placebo-controlled clinical trial (Prospective Rosacea Refractory Erythema Randomized Clinical Trial [PRRERCT]). Participants included patients aged 18 to 65 years with refractory rosacea (Clinician's Erythema Assessment [CEA] score ≥3). Plasma samples were collected at baseline and after 12 weeks of treatment. The data for this study were analyzed between September 2025 and November 2025.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Interventions: &lt;/strong&gt;Participants received oral paroxetine, 25 mg per day, for a 12-week treatment period.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Main outcomes and measures: &lt;/strong&gt;Systemic protein expression profiles were analyzed using data-independent acquisition liquid chromatography-tandem mass spectrometry. Clinical response was evaluated using CEA and the Flushing Assessment Tool. Correlations between proteomic changes and clinical improvements were assessed, and predictive biomarkers were identified using receiver operating characteristic curve analysis.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Among 24 participants (mean [SD] age, 35 [11] years; 24 [100%] female), paroxetine treatment significantly reduced mean (SD) CEA scores from 3.1 (0.3) to 2.3 (0.7) and Flushing Assessment Tool scores from 3.1 (0.6) to 2.0 (0.9) (P &lt; .001). Exploratory proteomic analysis revealed 497 candidate differentially expressed proteins after treatment. Downregulated proteins showed preliminary enrichment in pathways related to immune response activation, insulin receptor signaling, and neuronal remodeling. A subset of 98 reversed-response proteins was observed, primarily linked to synaptic vesicle cycles and vascular smooth muscle contraction. Proteomic alterations were associated with clinical improvement (65 proteins for erythema; 73 for flushing). Candidate biomarkers, notably OLFML3 (area under the receiver operating characteristic curve [AUC], 0.87 [95% CI, 0.70-1.00]) and IGFBP2 (AUC, 0.80 [95% CI 0.55-1.00]), demonstrated high predictive value for clinical response.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions and relevance: &lt;/strong&gt;In this secondary analysis of a randomized clinical trial, paroxetine treatment was associated with modulation of systemic neuro-vascular-immune networks in patients with rosacea. These exploratory findings provide preliminary mechanistic clues regarding the possible disease-modifying potential ","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":"804-812"},"PeriodicalIF":10.9,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13276666/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148264416","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Online vs In-Person Care for Atopic Dermatitis: A Randomized Clinical Trial.","authors":"April W Armstrong, Alyssa M Roberts, Gina Kostandy, Farzana Choudhury, Danielle Yee, Minnelly Luu, Madison E Jones, Elmar R Alizadeh, Jonathan Cotliar, Mary-Margaret Chren, Joel M Gelfand, Myles Cockburn, Jason N Doctor","doi":"10.1001/jamadermatol.2026.1959","DOIUrl":"10.1001/jamadermatol.2026.1959","url":null,"abstract":"<p><strong>Importance: </strong>Accessible and effective management of atopic dermatitis (AD) across geographic boundaries is important. Scalable, collaborative care models that integrate patients, primary care practitioners, and specialists remain an unmet need.</p><p><strong>Objective: </strong>To determine whether an online, team-based connected health (TCH) model provides equivalent improvements in AD severity compared to in-person care.</p><p><strong>Design, setting, and participants: </strong>In this pragmatic, randomized clinical equivalence trial, 300 patients with AD were enrolled from 8 outpatient dermatology clinics in California from August 2019 to May 2024 and randomized 1:1 to online or in-person care. Eligible participants were at least 1 year old and had a physician diagnosis of AD, internet and photograph access, and established or new clinician care.</p><p><strong>Intervention: </strong>The TCH model provided asynchronous, online access to dermatologists. Dermatologists reviewed patients' clinical histories and photographs and provided assessments and treatment recommendations online. The control arm provided conventional, in-person care.</p><p><strong>Main outcomes and measures: </strong>The primary outcome was 12-month change in the EASI (Eczema Area and Severity Index); secondary outcomes were changes in the POEM (Patient-Oriented Eczema Measure) and validated vIGA (Investigator Global Assessment), assessed quarterly.</p><p><strong>Results: </strong>Among 300 adults and children with AD (mean [SD] age, 34.6 [17.7] years; 211 [70.3%] female), 149 were assigned to TCH and 151 to in-person care. The difference in mean change between the 2 groups was -0.01 (95% CI, -0.22 to 0.20) for the EASI, 0.38 (95% CI, 0.03-0.73) for the POEM, and 0.06 (95% CI, 0.00-0.11) for the vIGA. All differences fell within prespecified equivalence margins.</p><p><strong>Conclusions and relevance: </strong>In this randomized clinical trial, the online TCH model resulted in equivalent improvements in AD signs and symptoms compared to in-person care. Telehealth models may serve as effective tools for managing chronic diseases like AD.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov Identifier: NCT03981926.</p>","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":"795-803"},"PeriodicalIF":10.9,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13294821/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148308072","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"GLP-1 Receptor Agonists in Hidradenitis Suppurativa-Emerging Opportunities for Comorbidity Management?","authors":"Haley B Naik, Diana Thiara","doi":"10.1001/jamadermatol.2026.1882","DOIUrl":"10.1001/jamadermatol.2026.1882","url":null,"abstract":"","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":"773-774"},"PeriodicalIF":10.9,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148360927","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development of a Core Outcome Domain Set for Facial Aging.","authors":"McKenzie A Dirr, Areeba Ahmed, Daniel I Schlessinger, Vanessa Lazaro-Camp, Sabrina Smith, Thanvi Gullapalli, Doroteja Dragovic, Joycie Chang, Elizabeth Zhang, Murad Alam, Noor Anvery, Rachel E Christensen, Sarah A Ibrahim, Bianca Y Kang, Clarissa Wong, Sanjana Iyengar, Arianna F Yanes, Jill Cotseones, Hovik J Ashchyan, Payal M Patel, Umar A Sheikh, Matthew J Franklin, Courtney C Hanna, Sarah G Chiren, Jochen Schmitt, Karina C Furlan, Macrene Alexiades, Raed Alhusayen, Tina S Alster, Kenneth Beer, Vince Bertucci, Jason D Bloom, César A Briceño, Vivian Bucay, Kimberly J Butterwick, Cartier Hugues, Gabriela Casabona, Karen L Connolly, Sebastian Cotofana, Martha Laurin Council, Sue Ellen Cox, Monica Darmanescu, Koenraad De Boulle, Shraddha Desai, Lisa M Donofrio, Jeffrey S Dover, Zoe Draelos, Daniel B Eisen, Moetaz El-Domyati, Yehia El-Garem, John Fischer, Rebecca Fitzgerald, Daniel P Friedmann, Hassan Galadari, Hayes B Gladstone, Mitchel P Goldman, Greg J Goodman, Jeremy B Green, Shlomit Halachmi, C William Hanke, Shannon Humphrey, Sherrif F Ibrahim, Jared Jagdeo, Shang I Brian Jiang, Julie K Karen, Arielle Kauvar, Abdul-Ghani Kibbi, John V S Kim, Jenny Kim, Davi de Lacerda, Gary Lask, Grace M Lopez, Mary P Lupo, Kavita Mariwalla, Seth Matarasso, Lally Mekokishvili, Rhoda S Narins, Patricia Ogilvie, Jeffrey S Orringer, Tammy H Osaki, David Ozog, Theresa Pacheco, Kristel Polder, Anthony M Rossi, Neil Sadick, Nazanin Saedi, Joel Schlessinger, Jaishree Sharad, Manjunath M Shenoy, Rodney Sinclair, Nowell Solish, Miriam Emily Piansay-Soriano, Omotara Sulyman, Rolf-Markus Szeimies, Elizabeth L Tanzi, Amy Forman Taub, Mark B Taylor, J Regan Thomas, Luis Torezan, Antonella Tosti, Dany Touma, Ada Regina Trindade de Almeida, Maya Vedamurthy, Giovanni Viana, Abigail Waldman, Susan H Weinkle, Robert Weiss, Emily Poon, Ian A Maher, Todd V Cartee, Joseph F Sobanko, Jamie J Kirkham","doi":"10.1001/jamadermatol.2026.1697","DOIUrl":"10.1001/jamadermatol.2026.1697","url":null,"abstract":"<p><strong>Importance: </strong>Currently, there are no standardized outcome domains or measures in clinical trials for facial aging. Heterogeneity in outcome domains and measurement instruments across clinical trials creates difficulty in directly comparing interventions, determining superior therapies, and developing high-quality meta-analyses.</p><p><strong>Objective: </strong>To develop a core outcome set (COS) of essential domains to be reported in clinical trials evaluating the efficacy of interventions for facial aging.</p><p><strong>Evidence review: </strong>PubMed/Medline, Embase, Cochrane Central Register of Controlled Trials, and CINAHL were searched from September 2005 to September 2015. An updated search of the same databases was performed from September 2015 to February 2026. Studies were included if (1) they were randomized clinical trial or controlled clinical trial in design, (2) they assessed the efficacy or safety of an intervention for facial aging, (3) they were published in English, and (4) they involved human participants. Complementary sources, including patient interviews, were used to capture further relevant outcomes. Two rounds of Delphi surveys, followed by consensus meetings, were used to identify outcome domains considered most important by both patient and physician stakeholders.</p><p><strong>Findings: </strong>The final COS consists of 6 outcome domains: (1) overall convenience of treatment; (2) time to return to normal work and social activity; (3) overall assessment of focused area of treatment (at the point in time when treatment is expected to provide peak benefit); (4) duration of treatment effect; (5) severity of persistent local or systemic adverse events, including pigmentary change, skin texture change, delayed healing, scarring, and serious adverse events; and (6) patient satisfaction with treatment.</p><p><strong>Conclusions and relevance: </strong>The 6 outcome domains identified through a Delphi consensus are recommended for reporting in future facial aging trials to ensure that outcomes that matter most to patients and clinicians are measured and that results are comparable across interventions.</p>","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":"829-836"},"PeriodicalIF":10.9,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148264333","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neoadjuvant Capecitabine in Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck.","authors":"Savanah Haidar, Alex Mlynarek, Philippe Lefrancois, Osama Roshdy, Manish Khanna, Geneviève Fortier-Riberdy, Keith Richardson, Livia Florianova, Marc Pusztaszeri, Derin Caglar, Nader Sadeghi, Michael Hier, Khalil Sultanem, Christina Tsien, Nathaniel Bouganim, Khashayar Esfahani, Marco A Mascarella","doi":"10.1001/jamadermatol.2026.1331","DOIUrl":"10.1001/jamadermatol.2026.1331","url":null,"abstract":"<p><strong>Importance: </strong>The incidence of cutaneous squamous cell carcinoma of the head and neck (cSCCHN) has increased, including among those with high-risk disease. Delays to access and initiation of care are associated with disease progression and worse outcomes. Capecitabine has previously been shown to be effective antitumor activity with low toxic effects.</p><p><strong>Objective: </strong>To evaluate the efficacy and tolerability of neoadjuvant capecitabine (NC) in advanced cSCCHN by evaluating the clinical and pathologic stage migration.</p><p><strong>Design, setting, and participants: </strong>This prospective case series was conducted from January 2024 to September 2025 at 2 academic centers in Montreal, Canada, and included consecutive patients with advanced cSCCHN who were awaiting surgery. The data were analyzed in November 2025.</p><p><strong>Intervention: </strong>Two cycles of NC (1000 mg, twice daily, on days 1-14, followed by a 1-week rest period) were administered according to the Capecitabine Prior to Tumor Resection in ENT Oncology (CAPTURE) protocol, with surgical resection performed within 1 to 2 weeks after treatment completion.</p><p><strong>Main outcomes and measures: </strong>Clinical tumor response and clinical to pathologic stage migration, defined as the comparison of initial clinical stage with the postsurgical pathologic stage.</p><p><strong>Results: </strong>The mean (SD) age of the cohort of 15 patients was 77 (8.1) years; 6 patients (40%) were female, and 9 patients (60%) were male. Clinical tumor regression was observed in 10 of 15 patients (67%). Among those who underwent resection, 5 (42%) achieved a complete pathologic response. Two patients avoided surgery due to complete treatment response and opted to receive radiotherapy. Nonresponse occurred for 5 patients, including 1 patient who experienced progression to metastatic disease. No grade 3 or higher capecitabine-related toxic effects were reported.</p><p><strong>Conclusions: </strong>This case series found that NC demonstrated significant tumor regression and pathologic response without severe treatment-related toxic effects. NC may be an effective treatment option for providing disease control and tumor downstaging in patients with advanced cSCCHN.</p>","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":"813-817"},"PeriodicalIF":10.9,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13217255/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148030623","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}